Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - psychoanaleptics

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - centrally acting sympathomimetics

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - psychoanaleptics

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - centrally acting sympathomimetics

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - psychoanaleptics

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - venlafaxine - prolonged-release capsule, hard - 150 milligram(s) - other antidepressants; venlafaxine

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - venlafaxine - prolonged-release capsule, hard - 75 milligram(s) - other antidepressants; venlafaxine

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 286.96 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 573.921 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide black; microcrystalline cellulose; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceuticals ireland limited - lisdexamfetamine dimesylate - capsule, hard - 20 milligram(s) - centrally acting sympathomimetics